This 4-year randomized open-label trial evaluated the long-term efficacy, safety, and tolerability of secukinumab in children and adolescents aged 6 to younger than 18 years with moderate-to-severe chronic plaque psoriasis.
This 4-year randomized open-label trial evaluated the long-term efficacy, safety, and tolerability of secukinumab in children and adolescents aged 6 to younger than 18 years with moderate-to-severe chronic plaque psoriasis.
